Anthony Traboulsee

Academic Appointment

Professor

Research Focus

Multiple Sclerosis MRI Scans

Degrees / Designations

Contact Info

t.traboulsee@ubc.ca

604-822-0788

http://ca.linkedin.com/pub/tony-traboulsee/4/441/b15/

Biography

Dr. Anthony Traboulsee is a professor and research chair of the Multiple Sclerosis (MS) Society of Canada at the University of British Columbia (UBC) and director of the UBC MS/Magnetic Resonance Imaging (MRI) Research Group. His research focus is on the development of practice guidelines for routine use of MRI in the management of MS, establishing advanced MRI imaging outcomes in MS, and the treatment of Neuromyelitis Optica.

Research Studies

Multiple Sclerosis

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (VISIONARY-MS)

Multiple Sclerosis

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (TOPAZ)

Multiple Sclerosis, Neurologic Diseases

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (IGLOO)

Multiple Sclerosis

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Multiple Sclerosis

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

News and Awards

Controversial “liberation therapy” fails to treat multiple sclerosis: UBC-Vancouver Coastal Health research

Mar 8, 2017

UBC-Vancouver Coastal Health scientists find genetic cause of multiple sclerosis

Jun 1, 2016

VCHRI centre recruits highest number of participants for international MS study

Nov 21, 2015

Often ignored aspect of MRI proves highly useful for brain scans

Nov 14, 2013

Study finds narrowing of veins is not unique to people with MS

Oct 8, 2013

Publications

The Lancet. Neurology -
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA
Multiple sclerosis and related disorders -
Brain health: time matters in multiple sclerosis.
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T
The New England journal of medicine -
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L,
Brain : a journal of neurology -
Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.
Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA
The New England journal of medicine -
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS,

Anthony Traboulsee

Biography

Research Studies

News and Awards

Publications

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Brain health: time matters in multiple sclerosis.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Are you a researcher?